5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders

Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders

This section covers high-grade aggressive lymphomas, plasma cell dyscrasias, and post-thymic mature T-cell/NK-cell neoplasms. Rapid laboratory identification, flow cytometric immunophenotyping, and cytogenetic characterization are essential for establishing prompt diagnoses and directing emergency therapeutic interventions.

---

1. Aggressive Mature B-Cell Lymphomas

                         AGGRESSIVE B-CELL LYMPHOMAS
                                      │
     ┌────────────────────────────────┴────────────────────────────────┐
     ▼                                                                 ▼
[ DIFFUSE LARGE B-CELL LYMPHOMA ]                            [ BURKITT LYMPHOMA ]
• Most Common NHL (30-40%)                                   • Fast Doubling Time (~24 hrs)
• Large Cells (≥2× Lymphocyte)                               • EBV Association
• CD19+, CD20+, CD79a+, PAX5+                                • "Starry Sky" Histology
• Double-Hit: MYC + BCL2/BCL6                                • Basophilic Vacuolated Blasts
                                                             • t(8;14) MYC::IGH Translocation
                                                             • Ki-67 Proliferation Index ~100%

A. Diffuse Large B-Cell Lymphoma (DLBCL)

• Epidemiology: The most common subtype of non-Hodgkin lymphoma worldwide, accounting for 30% to 40% of newly diagnosed adult lymphomas. Presents as a rapidly expanding nodal or extranodal mass (e.g., gastrointestinal tract, bone, brain, Waldeyer ring).
• Morphology: Complete effacement of normal tissue architecture by diffuse sheets of large lymphoid cells. Neoplastic cells have diameters $\ge 2\times$ the size of a normal resting lymphocyte (or larger than a histiocyte nucleus), with vesicular chromatin, 1 to 3 prominent nucleoli, and moderate amounts of basophilic cytoplasm.
• Immunophenotype: Broad pan-B-cell marker expression: CD19+, CD20+, CD22+, CD79a+, and PAX5+.
• Molecular Subtypes & Double-Hit Lymphoma: Gene expression profiling classifies DLBCL into Germinal Center B-cell-like (GCB) and Activated B-cell-like (ABC) subtypes (the Hans immunohistochemical algorithm uses CD10, BCL6, and MUM1 as surrogates). High-Grade B-cell Lymphoma with Double-Hit or Triple-Hit Genetics harbors concurrent chromosomal translocations involving $MYC$ (8q24) and $BCL2$ (18q21) and/or $BCL6$ (3q27), conferring extreme chemoresistance and poor prognosis.

B. Burkitt Lymphoma (BL)

• Epidemiology & Variants: One of the fastest-growing human malignancies, with a potential tumor doubling time of approximately 24 hours. Occurs in three clinical settings: Endemic (equatorial Africa; pediatric jaw/facial bone tumors; $>95\%$ associated with Epstein-Barr Virus [EBV]), Sporadic (worldwide; children and young adults; abdominal/ileocecal mass), and Immunodeficiency-Associated (HIV infection).
• Cytogenetics: Hallmark reciprocal translocation $\text{t}(8;14)(\text{q}24;\text{q}32)$ in $>85\%$ of cases, translocating the $MYC$ proto-oncogene on 8q24 to the $IGH$ enhancer locus on 14q32. Variant translocations include $\text{t}(2;8)(\text{p}12;\text{q}24)$ [$IGK::MYC$] and $\text{t}(8;22)(\text{q}24;\text{q}11.2)$ [$MYC::IGL$]. Constitutive MYC oncoprotein overexpression drives continuous transcription of cell-cycle genes.
• Histology & Cytology:
  • "Starry Sky" Histology: Low-power tissue microscopy reveals a dark background ("sky") of monomorphic basophilic neoplastic B-cells undergoing high rates of apoptosis, interspersed with numerous pale tingible-body macrophages ("stars") containing ingested apoptotic debris and clear lipid vacuoles.
  • Smear / Touch Prep: Monomorphic intermediate-sized lymphocytes with round nuclei, coarsely clumped chromatin, multiple prominent basophilic nucleoli, and deeply royal-blue cytoplasm filled with numerous sharply defined, lipid-containing vacuoles (which stain positively with Oil Red O).
• Immunophenotype & Ki-67: CD19+, CD20+ (bright), CD10+, BCL6+, surface IgM+ with light chain restriction, and BCL2 NEGATIVE (essential for distinguishing from double-hit DLBCL). The Ki-67 (MIB-1) proliferation fraction is virtually 100%.
• Tumor Lysis Syndrome (TLS): Massive cellular turnover and rapid response to cytotoxic chemotherapy release intracellular contents, causing life-threatening hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia with acute uric acid nephropathy.

---

2. Classical Hodgkin Lymphoma (cHL)

Classical Hodgkin Lymphoma is a unique mature B-cell-derived neoplasm characterized by a tiny population ($<1\%$) of clonal malignant giant cells surrounded by an overwhelming background of non-neoplastic, reactive inflammatory cells.

                   CLASSICAL HODGKIN LYMPHOMA ARCHITECTURE

 ┌─────────────────────────────────────────────────────────────────────────┐
 │                     REACTIVE INFLAMMATORY BACKGROUND                    │
 │  (Polyclonal CD4+ T-Cells, Eosinophils, Plasma Cells, Histiocytes)      │
 │                                                                         │
 │          ┌──────────────────────────────────────────────────┐           │
 │          │       MALIGNANT REED-STERNBERG (RS) CELLS        │           │
 │          │ • Large Binucleated / Multinucleated Giant Cells │           │
 │          │ • Prominent Eosinophilic "Owl-Eye" Nucleoli      │           │
 │          │ • Perinuclear Clear Halos                        │           │
 │          │ • Immunophenotype: CD30+, CD15+, PAX5+ (Dim)     │           │
 │          │   CD45- (LCA Negative), CD20-, CD3-              │           │
 │          └──────────────────────────────────────────────────┘           │
 └─────────────────────────────────────────────────────────────────────────┘

Epidemiology & Clinical Features

• Bimodal Age Distribution: Peaks in young adults aged 15 to 35 years, with a second peak in adults $>55$ years.
• Presentation: Painless, rubbery cervical, supraclavicular, or mediastinal lymphadenopathy. Patients frequently experience B-symptoms (unexplained fever $>38^\circ\text{C}$, drenching night sweats, $>10\%$ weight loss over 6 months), generalized pruritus, and pain in diseased lymph nodes following alcohol ingestion.

Diagnostic Cytology

• Reed-Sternberg (RS) Cell: The diagnostic hallmark. A giant cell ($20\text{--}>50\ \mu\text{m}$) containing two or more mirror-image nuclear lobes ("owl-eye" appearance) or multinucleated configurations. Each lobe contains an enormous, inclusion-like, purple-red eosinophilic nucleolus surrounded by a clear perinuclear halo.
• Mononuclear Hodgkin Cell: Single-nucleus variants with identical prominent eosinophilic nucleoli.
• Lacunar Cell: Specialized RS variant seen in the Nodular Sclerosis subtype; the cytoplasm retracts during formalin fixation, leaving the nucleus sitting in an empty space or "lacuna".
• Reactive Microenvironment: Malignant RS cells secrete cytokines (IL-5, IL-13, TGF-$\beta$, CCL28) that recruit small non-clonal CD4+ T-lymphocytes (which form rosettes around RS cells), eosinophils, plasma cells, and histiocytes.

Subtypes of Classical Hodgkin Lymphoma

1. Nodular Sclerosis (NS-cHL): Most common subtype (~70%); young adults, female predominance; mediastinal mass; dense broad collagen bands dividing lymph node into nodules; lacunar cells.
2. Mixed Cellularity (MC-cHL): ~20–25%; older patients, male predominance; rich in eosinophils, plasma cells, and histiocytes; high association with EBV (~75%).
3. Lymphocyte-Rich (LR-cHL): ~5%; background dominated by mature small lymphocytes with classic RS cells; favorable prognosis.
4. Lymphocyte-Depleted (LD-cHL): $<1\%$; abundant pleomorphic RS cells with few background lymphocytes; aggressive, elderly/HIV+ patients. (Note: Nodular Lymphocyte Predominant Hodgkin Lymphoma [NLPHL] is a separate, non-classical entity characterized by "popcorn cells" [LP cells] expressing CD20+, CD45+, CD30-, CD15-).

Diagnostic Immunophenotype of Classical RS Cells

• CD30+ (Ki-1): Strong membranous and Golgi-zone dot-like staining in virtually 100% of cases.
• CD15+ (Leu-M1): Positive in $75\text{--}85\%$ of cases.
• PAX5+ (Dim / Weak): Weak B-cell transcription factor positivity (proves B-cell origin despite loss of immunoglobulin synthesis).
• CD45 (LCA) NEGATIVE: Malignant RS cells lose leukocyte common antigen.
• CD20 Negative (or weak/focal variable); CD3 NEGATIVE.

---

3. Mature T-Cell & NK-Cell Disorders

Mature T-cell neoplasms are uncommon ($<10\%$ of all non-Hodgkin lymphomas) and arise from post-thymic mature T-lymphocytes.

                         MATURE T-CELL NEOPLASMS
                                    │
     ┌──────────────────────────────┴──────────────────────────────┐
     ▼                                                             ▼
[ SÉZARY SYNDROME / MF ]                                  [ ADULT T-CELL LEUKEMIA/LYMPHOMA ]
• Cutaneous T-Cell Lymphoma                               • HTLV-1 Retrovirus Association
• Triad: Erythroderma + Lymphadenopathy                   • Japan, Caribbean, South America
  + Circulating Sézary Cells (≥1.0 × 10^9/L)              • Profound Hypercalcemia & Bone Lesions
• Cerebriform / Brain-like Folded Nuclei                  • "Flower Cells" / Clover-Leaf Nuclei
• CD3+, CD4+, CD7 Negative, CD26 Negative                 • CD3+, CD4+, CD25+ (Bright)

A. Mycosis Fungoides (MF) & Sézary Syndrome (SS)

• Mycosis Fungoides: The most common cutaneous T-cell lymphoma (CTCL), characterized by skin-homing CD4+ memory helper T-cells producing erythematous patches, plaques, and cutaneous tumors with epidermal infiltration (Pautrier microabscesses).
• Sézary Syndrome Triad: The leukemic, aggressive variant of CTCL, clinically defined by the triad of:
  1. Erythroderma: Diffuse, intensely pruritic, exfoliative redness covering $>80\%$ of the body surface area.
  2. Generalized Lymphadenopathy.
  3. Circulating Sézary Cells: Clonal circulating T-cells $\ge 1.0 \times 10^9/\text{L}$ ($1,000/\mu\text{L}$) or $\ge 10\%$ of lymphocytes.
• Sézary Cell Morphology: Medium-to-large mature lymphocytes with highly distinctive cerebriform / hyperconvoluted / brain-like grooved nuclei with condensed chromatin and scant cytoplasm.
• Immunophenotype: Mature T-helper profile: CD2+, CD3+, CD4+, CD5+, with characteristic loss of CD7 (CD7 NEGATIVE) and loss of CD26 (CD26 NEGATIVE); CD8 negative.

B. Adult T-Cell Leukemia / Lymphoma (ATLL)

• Etiology & Epidemiology: Caused by infection with the Human T-Cell Lymphotropic Virus type 1 (HTLV-1) retrovirus. Endemic in Southwestern Japan, the Caribbean basin, parts of Central/South America, and equatorial Africa.
• Clinical Features: Acute ATLL presents aggressively with marked leukocytosis, profound hypercalcemia (due to tumor secretion of PTHrP), lytic bone lesions, hepatosplenomegaly, skin lesions, and generalized lymphadenopathy.
• Pathognomonic Cytology: "Flower Cells" (Clover-Leaf Cells)—circulating atypical lymphocytes with deeply indented, polylobated nuclear contours resembling the petals of a flower, with condensed chromatin and basophilic cytoplasm.
• Immunophenotype: CD3+, CD4+, CD25+ (IL-2 receptor $\alpha$-chain, uniformly bright positive), CD7 negative, CD8 negative.